Inherited forms of mineralocorticoid hypertension

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 18, Issue 3, 2011, Pages 177-185

  Hassan Smith, Zaki ^a   Stewart, Paul M ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

11 hydroxysteroid dehydrogenase; apparent mineralocorticoid excess; epithelial sodium channel; hyperaldosteronism; mineralocorticoid hypertension

Indexed keywords

DEXAMETHASONE; MINERALOCORTICOID; SPIRONOLACTONE; STEROID 11BETA MONOOXYGENASE; STEROID 17ALPHA MONOOXYGENASE;

11BETA HYDROXYLASE DEFICIENCY; ARTICLE; CLINICAL FEATURE; CONGENITAL ADRENAL HYPERPLASIA; DRUG MEGADOSE; ENZYME DEFICIENCY; ESSENTIAL HYPERTENSION; FAMILIAL HYPERALDOSTERONISM TYPE 1; FAMILIAL HYPERALDOSTERONISM TYPE 2; GORDON SYNDROME; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; HYPOKALEMIA; LIDDLE SYNDROME; LOW DRUG DOSE; STEROID 17ALPHA MONOOXYGENASE DEFICIENCY;

ADRENAL HYPERPLASIA, CONGENITAL; BIOLOGICAL MARKERS; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; LIDDLE SYNDROME; MINERALOCORTICOID EXCESS SYNDROME, APPARENT; MINERALOCORTICOIDS; MUTATION; PSEUDOHYPOALDOSTERONISM; RECEPTORS, MINERALOCORTICOID;

EID: 79955600669     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0b013e3283469444     Document Type: Article

References (105)

1. Tomlinson JW, Walker EA, Bujalska IJ, et al. 11beta-hydroxysteroid dehydrogenase type 1: A tissue-specific regulator of glucocorticoid response. Endocr Rev 2004; 25:831-866. (Pubitemid 39366049)
2. New MI, Levine LS, Biglieri EG, et al. Evidence for an unidentified steroid in a child with apparent mineralocorticoid hypertension. J Clin Endocrinol Metab 1977; 44:924-933. (Pubitemid 8104640)
3. Palermo M, Quinkler M, Stewart PM. Apparent mineralocorticoid excess syndrome: An overview. Arq Bras Endocrinol Metabol 2004; 48:687-696.
4. Shackleton CH, Rodriguez J, Arteaga E, et al. Congenital 11 beta-hydroxysteroid dehydrogenase deficiency associated with juvenile hypertension: Corticosteroid metabolite profiles of four patients and their families. Clin Endocrinol (Oxf) 1985; 22:701-712. (Pubitemid 15046171)
5. Monder C, Shackleton CH, Bradlow HL, et al. The syndrome of apparent mineralocorticoid excess: Its association with 11 beta-dehydrogenase and 5 beta-reductase deficiency and some consequences for corticosteroid metabolism. J Clin Endocrinol Metab 1986; 63:550-557. (Pubitemid 16050550)
6. Stewart PM, Krozowski ZS, Gupta A, et al. Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11 beta-hydroxysteroid dehydrogenase type 2 gene. Lancet 1996; 347:88-91. (Pubitemid 26017854)
7. White PC, Mune T, Rogerson FM, et al. Molecular analysis of 11 betahydroxysteroid dehydrogenase and its role in the syndrome of apparent mineralocorticoid excess. Steroids 1997; 62:83-88. (Pubitemid 27065446)
8. Draper N, Stewart PM. 11beta-hydroxysteroid dehydrogenase and the prereceptor regulation of corticosteroid hormone action. J Endocrinol 2005; 186:251-271. (Pubitemid 41167396)
9. Agarwal AK, Rogerson FM, Mune T, White PC. Analysis of the human gene encoding the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase. J Steroid Biochem Mol Biol 1995; 55:473-479. (Pubitemid 26022381)
10. Quinkler M, Bappal B, Draper N, et al. Molecular basis for the apparent mineralocorticoid excess syndrome in the Oman population. Mol Cell Endocrinol 2004; 217:143-149. (Pubitemid 38596639)
11. Lavery GG, Ronconi V, Draper N, et al. Late-onset apparent mineralocorticoid excess caused by novel compound heterozygous mutations in the HSD11B2 gene. Hypertension 2003; 42:123-129. (Pubitemid 36944584)
12. Carvajal CA, Gonzalez AA, Romero DG, et al. Two homozygous mutations in the 11 beta-hydroxysteroid dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess. J Clin Endocrinol Metab 2003; 88: 2501-2507. (Pubitemid 36724415)
13. Dave-Sharma S, Wilson RC, Harbison MD, et al. Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess. J Clin Endocrinol Metab 1998; 83:2244-2254. (Pubitemid 28503009)
14. Li A, Li KX, Marui S, Krozowski ZS, et al. Apparent mineralocorticoid excess in a Brazilian kindred: Hypertension in the heterozygote state. J Hypertens 1997; 15 (12 Pt 1):1397-1402. (Pubitemid 28039566)
15. Kitanaka S, Katsumata N, Tanae A, et al. A new compound heterozygous mutation in the 11 beta-hydroxysteroid dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess. J Clin Endocrinol Metab 1997; 82:4054-4058. (Pubitemid 27525511)
16. Ferrari P, Obeyesekere VR, Li K, et al. Point mutations abolish 11 betahydroxysteroid dehydrogenase type II activity in three families with the congenital syndrome of apparent mineralocorticoid excess. Mol Cell Endocrinol 1996; 119:21-24.
17. Kitanaka S, Tanae A, Hibi I. Apparent mineralocorticoid excess due to 11 beta-hydroxysteroid dehydrogenase deficiency: A possible cause of intrauterine growth retardation. Clin Endocrinol (Oxf) 1996; 44:353-359.
18. Wilson RC, Harbison MD, Krozowski ZS, et al. Several homozygous mutations in the gene for 11 beta-hydroxysteroid dehydrogenase type 2 in patients with apparent mineralocorticoid excess. J Clin Endocrinol Metab 1995; 80:3145-3150.
19. New MI. The prismatic case of apparent mineralocorticoid excess. J Clin Endocrinol Metab 1994; 79:1-3. (Pubitemid 24221147)
20. Ulick S, Levine LS, Gunczler P, et al. A syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of cortisol. J Clin Endocrinol Metab 1979; 49:757-764. (Pubitemid 10198311)
21. Coeli FB, Ferraz LF, Lemos-Marini SH, et al. Apparent mineralocorticoid excess syndrome in a Brazilian boy caused by the homozygous missense mutation p.R186C in the HSD11B2 gene. Arq Bras Endocrinol Metabol 2008; 52:1277-1281.
22. Morineau G, Sulmont V, Salomon R, et al. Apparent mineralocorticoid excess: Report of six new cases and extensive personal experience. J Am Soc Nephrol 2006; 17:3176-3184. (Pubitemid 44707778)
23. Stewart PM, Wallace AM, Valentino R, et al. Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age. Lancet 1987; 2:821-824.
24. Inagaki K, Otsuka F, Otani H, et al. Apparent mineralocorticoid excess manifested in an elderly patient with hypothyroidism. Am J Hypertens 2007; 20:104-107; discussion 108. (Pubitemid 46014065)
25. Palermo M, Cossu M, Shackleton CH. Cure of apparent mineralocorticoid excess by kidney transplantation. N Engl J Med 1998; 339:1787-1788. (Pubitemid 28555443)
26. Sutherland DJ, Ruse JL, Laidlaw JC. Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Can Med Assoc J 1966; 95:1109-1119.
27. Rich GM, Ulick S, Cook S, et al. Glucocorticoid-remediable aldosteronism in a large kindred: Clinical spectrum and diagnosis using a characteristic biochemical phenotype. Ann Intern Med 1992; 116:813-820. (Pubitemid 23034758)
28. Pascoe L, Jeunemaitre X, Lebrethon MC, et al. Glucocorticoid-suppressible hyperaldosteronism and adrenal tumors occurring in a single French pedigree. J Clin Invest 1995; 96:2236-2246.
29. MacConnachie AA, Kelly KF, McNamara A, et al. Rapid diagnosis and identification of cross-over sites in patients with glucocorticoid remediable aldosteronism. J Clin Endocrinol Metab 1998; 83:4328-4331. (Pubitemid 29100130)
30. Yokota K, Ogura T, Kishida M, et al. Japanese family with glucocorticoidremediable aldosteronism diagnosed by long-polymerase chain reaction. Hypertens Res 2001; 24:589-594. (Pubitemid 33048926)
31. Ding W, Liu L, Hu R, et al. Clinical and gene mutation studies on a Chinese pedigree with glucocorticoid-remediable aldosteronism. Chin Med J (Engl) 2002; 115:979-982. (Pubitemid 34830766)
32. Mulatero P, di Cella SM, Williams TA, et al. Glucocorticoid remediable aldosteronism: Low morbidity and mortality in a four-generation Italian pedigree. J Clin Endocrinol Metab 2002; 87:3187-3191. (Pubitemid 34816363)
33. Vonend O, Altenhenne C, Buchner NJ, et al. A German family with glucocorticoid- remediable aldosteronism. Nephrol Dial Transplant 2007; 22: 1123-1130. (Pubitemid 46523427)
34. Lee IS, Kim SY, Jang HW, et al. Genetic analyses of the chimeric CYP11B1/ CYP11B2 gene in a Korean family with glucocorticoid-remediable aldosteronism. J Korean Med Sci 2010; 25:1379-1383. This paper describes the GRA gene mutation in a Korean family.
35. Chu MD, Ulick S. Isolation and identification of 18-hydroxycortisol from the urine of patients with primary aldosteronism. J Biol Chem 1982; 257:2218-2224. (Pubitemid 12069774)
36. Ulick S, Chan CK, Gill JR Jr, et al. Defective fasciculata zone function as the mechanism of glucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 1990; 71:1151-1157.
37. Lifton RP, Dluhy RG, Powers M, et al. A chimaeric 11 beta-hydroxylase/ aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992; 355:262-265.
38. Jonsson JR, Klemm SA, Tunny TJ, et al. A new genetic test for familial hyperaldosteronism type I aids in the detection of curable hypertension. Biochem Biophys Res Commun 1995; 207:565-571.
39. Fallo F, Pilon C, Williams TA, et al. Coexistence of different phenotypes in a family with glucocorticoid-remediable aldosteronism. J Hum Hypertens 2004; 18:47-51. (Pubitemid 38165521)
40. Gates LJ, Benjamin N, Haites NE, et al. Is random screening of value in detecting glucocorticoid-remediable aldosteronism within a hypertensive population? J Hum Hypertens 2001; 15:173-176. (Pubitemid 32181482)
41. Mulatero P, Veglio F, Pilon C, et al. Diagnosis of glucocorticoid- remediable aldosteronism in primary aldosteronism: Aldosterone response to dexamethasone and long polymerase chain reaction for chimeric gene. J Clin Endocrinol Metab 1998; 83:2573-2575. (Pubitemid 28503065)
42. Pizzolo F, Trabetti E, Guarini P, et al. Glucocorticoid remediable aldosteronism (GRA) screening in hypertensive patients from a primary care setting. J Hum Hypertens 2005; 19:325-327. (Pubitemid 40514912)
43. Litchfield WR, Anderson BF, Weiss RJ, et al. Intracranial aneurysm and hemorrhagic stroke in glucocorticoid-remediable aldosteronism. Hypertension 1998; 31 (1 Pt 2):445-450.
44. Dluhy RG, Lifton RP. Glucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 1999; 84:4341-4344.
45. Stowasser M, Gordon RD, Tunny TJ, et al. Familial hyperaldosteronism type II: Five families with a new variety of primary aldosteronism. Clin Exp Pharmacol Physiol 1992; 19:319-322.
46. Torpy DJ, Gordon RD, Lin JP, et al. Familial hyperaldosteronism type II: Description of a large kindred and exclusion of the aldosterone synthase (CYP11B2) gene. J Clin Endocrinol Metab 1998; 83:3214-3218. (Pubitemid 28500961)
47. Sukor N,Mulatero P,Gordon RD, et al. Further evidence for linkage of familial hyperaldosteronism type II at chromosome 7p22 in Italian as well as Australian and South American families. J Hypertens 2008; 26:1577-1582.
48. So A, Duffy DL, Gordon RD, et al. Familial hyperaldosteronism type II is linked to the chromosome 7p22 region but also shows predicted heterogeneity. J Hypertens 2005; 23:1477-1484. (Pubitemid 41104818)
49. Jeske YW, So A, Kelemen L, et al. Examination of chromosome 7p22 candidate genes RBaK, PMS2 and GNA12 in familial hyperaldosteronism type II. Clin Exp Pharmacol Physiol 2008; 35:380-385. (Pubitemid 351337333)
50. Carss KJ, Stowasser M, Gordon RD, O'Shaughnessy KM. Further study of chromosome 7p22 to identify the molecular basis of familial hyperaldosteronism type II. J Hum Hypertens 2010. [Epub ahead of print] This study examined the coding regions of five candidate genes at 7p22 and did not show any significant deletions or insertions. Of 15 SNPs identified none segregated with affected or unaffected individuals.
51. Liddle GW, Bledsoe T, Coppage W. A familial renal disorder simulating primary aldosteronism but with negligible aldosterone secretion. Trans Assoc Am Phys 1963; 76:199-213.
52. Shimkets RA, Warnock DG, Bositis CM, et al. Liddle's syndrome: Heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell 1994; 79:407-414. (Pubitemid 24346056)
53. Hansson JH, Nelson-Williams C, Suzuki H, et al. Hypertension caused by a truncated epithelial sodium channel gamma subunit: Genetic heterogeneity of Liddle syndrome. Nat Genet 1995; 11:76-82.
54. Tamura H, Sasaki S. Liddle syndrome. Nippon Rinsho 1996; 54:807-811.
55. Wang W, Zhou W, Jiang L, et al. Mutation analysis of SCNN1B in a family with Liddle's syndrome. Endocrine 2006; 29:385-390. (Pubitemid 44358825)
56. Rossi E, Farnetti E, Debonneville A, et al. Liddle's syndrome caused by a novel missense mutation (P617L) of the epithelial sodium channel beta subunit. J Hypertens 2008; 26:921-927. (Pubitemid 351520979)
57. Sawathiparnich P, Sumboonnanonda A, Weerakulwattana P, Limwongse C. A novel mutation in the beta-subunit of the epithelial sodium channel gene (SCNN1B) in a Thai family with Liddle's syndrome. J Pediatr Endocrinol Metab 2009; 22:85-89. This study describes a novel mutation (P615H) in the proline-rich motif of the beta subunit of ENaC.
58. Shi JY, Chen X, Ren Y, et al. Liddle's syndrome caused by a novel mutation of the gamma-subunit of epithelial sodium channel gene SCNN1G[in Chinese]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2010; 27:132-135. This paper describes a novel mutation (Q567X) in the ENaC gamma subunit gene in a Chinese family.
59. Wang Y, Zheng Y, Chen J, et al. A novel epithelial sodium channel gammasubunit de novo frameshift mutation leads to Liddle syndrome. Clin Endocrinol (Oxf) 2007; 67:801-804. (Pubitemid 47620449)
60. Snyder PM, Price MP, McDonald FJ, et al. Mechanism by which Liddle's syndrome mutations increase activity of a human epithelial Na+ channel. Cell 1995; 83:969-978. (Pubitemid 26006538)
61. Bubien JK. Epithelial Na+ channel (ENaC), hormones, and hypertension. J Biol Chem 2010; 285:23527-23531. This minireview provides an overview of the role of ENaC stimulation in human hypertension.
62. Paver WK, Pauline GJ. Hypertension and hyperpotassaemia without renal disease in a young male. Med J Aust 1964; 2:305-306.
63. Gordon RD, Geddes RA, Pawsey CG, O'Halloran MW. Hypertension and severe hyperkalaemia associated with suppression of renin and aldosterone and completely reversed by dietary sodium restriction. Australas Ann Med 1970; 19:287-294.
64. Spitzer A, Edelmann CM Jr, Goldberg LD, Henneman PH. Short stature, hyperkalemia and acidosis: A defect in renal transport of potassium. Kidney Int 1973; 3:251-257.
65. Weinstein SF, Allan DM, Mendoza SA. Hyperkalemia acidosis, and short stature associated with a defect in renal potassium excretion. J Pediatr 1974; 85:355-358.
66. Schambelan M, Sebastian A, Rector FC Jr. Mineralocorticoid-resistant renal hyperkalaemia without salt wasting (type II pseudohypoaldosteronism): Role of increased renal chloride reabsorption. Kidney Int 1981; 19:716-727. (Pubitemid 11064677)
67. Take C, Ikeda K, Kurasawa T, Kurokawa K. Increased chloride reabsorption as an inherited renal tubular defect in familial type II pseudohypoaldosteronism. N Engl J Med 1991; 324:472-476.
68. Mayan H, Vered I, Mouallem M, et al. Pseudohypoaldosteronism type II: Marked sensitivity to thiazides, hypercalciuria, normomagnesemia, and low bone mineral density. J Clin Endocrinol Metab 2002; 87:3248-3254. (Pubitemid 34816373)
69. Wilson FH, Disse-Nicodeme S, Choate KA, et al. Human hypertension caused by mutations in WNK kinases. Science 2001; 293:1107-1112. (Pubitemid 32758085)
70. Golbang AP, Cope G, Hamad A, et al. Regulation of the expression of the Na/ Cl cotransporter by WNK4 and WNK1: Evidence that accelerated dynamindependent endocytosis is not involved. Am J Physiol Renal Physiol 2006; 291:F1369-F1376. (Pubitemid 44887251)
71. McCormick JA, Ellison DH. The WNKs: Atypical protein kinases with pleiotropic actions. Physiol Rev 2011; 91:177-219. This review outlines WNK signalling actions, and the effects of defective actions in Gordon's syndrome and possible role in Essential Hypertension.
72. Moriguchi T, Urushiyama S, Hisamoto N, et al. WNK1 regulates phosphorylation of cation-chloride-coupled cotransporters via the STE20-related kinases, SPAK and OSR1. J Biol Chem 2005; 280:42685-42693. (Pubitemid 43049227)
73. Geller DS, Rodriguez-Soriano J, Vallo Boado A, et al. Mutations in the mineralocorticoid receptor gene cause autosomal dominant pseudohypoaldosteronism type I. Nat Genet 1998; 19:279-281. (Pubitemid 28309343)
74. Vingerhoeds AC, Thijssen JH, Schwarz F. Spontaneous hypercortisolism without Cushing's syndrome. J Clin Endocrinol Metab 1976; 43:1128-1133.
75. Charmandari E, Kino T, Ichijo T, Chrousos GP. Generalized glucocorticoid resistance: Clinical aspects, molecular mechanisms, and implications of a rare genetic disorder. J Clin Endocrinol Metab 2008; 93:1563-1572. (Pubitemid 351656488)
76. McMahon SK, Pretorius CJ, Ungerer JP, et al. Neonatal complete generalized glucocorticoid resistance and growth hormone deficiency caused by a novel homozygous mutation in Helix 12 of the ligand binding domain of the glucocorticoid receptor gene (NR3C1). J Clin Endocrinol Metab 2010; 95:297-302. This paper reports a case of GGR in a neonate and highlights the possible presentation of hypoglycaemia.
77. Nader N, Bachrach BE, Hurt DE, et al. A novel point mutation in helix 10 of the human glucocorticoid receptor causes generalized glucocorticoid resistance by disrupting the structure of the ligand-binding domain. J Clin Endocrinol Metab 2010; 95:2281-2285. This paper also reports a case of GGR presenting with hypoglycaemia in childhood.
78. Hurley DM, Accili D, Stratakis CA, et al. Point mutation causing a single amino acid substitution in the hormone binding domain of the glucocorticoid receptor in familial glucocorticoid resistance. J Clin Invest 1991; 87: 680-686.
79. Trebble P, Matthews L, Blaikley J, et al. Familial glucocorticoid resistance caused by a novel frameshift glucocorticoid receptor mutation. J Clin Endocrinol Metab 2010; 95:E490-E499. This paper reports a novel frameshift mutation in a case of GGR.
80. Karl M, Lamberts SW, Detera-Wadleigh SD, et al. Familial glucocorticoid resistance caused by a splice site deletion in the human glucocorticoid receptor gene. J Clin Endocrinol Metab 1993; 76:683-689. (Pubitemid 23086488)
81. Bouligand J, Delemer B, Hecart AC, et al. Familial glucocorticoid receptor haploinsufficiency by nonsense mediated mRNA decay, adrenal hyperplasia and apparent mineralocorticoid excess. PLoS One 2010; 5: E13563. This paper describes the first known missense mutation in GGR.
82. Krone N, Grotzinger J, Holterhus PM, et al. Congenital adrenal hyperplasia due to 11-hydroxylase deficiency: Insights from two novel CYP11B1 mutations (p.M92X, p R453Q). Horm Res 2009; 72:281-286. This publication describes two novel mutations in a patient with classic 11b-hydroxylase deficiency. In-vitro analysis demonstrated loss of function.
83. New MI. Hypertension in congenital adrenal hyperplasia and apparent mineralocorticoid excess. Ann N Y Acad Sci 2002; 970:145-154. (Pubitemid 35286091)
84. White PC. Inherited forms of mineralocorticoid hypertension. Hypertension 1996; 28:927-936. (Pubitemid 26415807)
85. White PC, Dupont J, New MI, et al. A mutation in CYP11B1 (Arg-448 - His) associated with steroid 11 beta-hydroxylase deficiency in Jews of Moroccan origin. J Clin Invest 1991; 87:1664-1667.
86. Zhao LQ, Han S, Tian HM. Progress in molecular-genetic studies on congenital adrenal hyperplasia due to 11beta-hydroxylase deficiency. World J Pediatr 2008; 4:85-90. (Pubitemid 351736690)
87. Riedl S, Nguyen HH, Clausmeyer S, et al. A homozygous L299P mutation in the CYP11B1 gene leads to complete virilization in 46 XX individuals with 11-beta-hydroxylase deficiency. Horm Res 2008; 70:145-149.
88. Soardi FC, Penachioni JY, JustoGZ, et al. Novel mutations in CYP11B1 gene leading to 11 beta-hydroxylase deficiency in Brazilian patients. J Clin Endocrinol Metab 2009; 94:3481-3485. In this study two novel mutations are described that cause loss of enzyme function due to altered protein structure in Brazilian patients.
89. Krone N, Arlt W. Genetics of congenital adrenal hyperplasia. Best Pract Res Clin Endocrinol Metab 2009; 23:181-192. This review provides an overview of the genetics of all four forms of congenital adrenal hyperplasia.
90. Dumic K, Wilson R, Thanasawat P, et al. Steroid 11-beta hydroxylase deficiency caused by compound heterozygosity for a novel mutation in intron 7 (IVS 7 DS+4A to G) in one CYP11B1 allele and R448H in exon 8 in the other. Eur J Pediatr 2010; 169:891-894. This paper reports the results of the first molecular analysis of the CYP11B1 gene in a Croatian patient with Congenital Adrenal Hyperplasia. A novel mutation (IVS 7DS+4AtoG) is identified.
91. Parajes S, Loidi L, Reisch N, et al. Functional consequences of seven novel mutations in the CYP11B1 gene: Four mutations associated with nonclassic and three mutations causing classic 11{beta}-hydroxylase deficiency. J Clin Endocrinol Metab 2010; 95:779-788. Functional status of the enzymes encoded by CYP11B1 mutations is shown to correlate with phenotypic severity of disease in this study.
92. Chabraoui L, Abid F, Menassa R, et al. Three novel CYP11B1 mutations in congenital adrenal hyperplasia due to steroid 11beta-hydroxylase deficiency in a moroccan population. Horm Res Paediatr 2010; 74:182-189. This paper describes the presentations of patients with a further three novel mutations in CYP11B1.
93. Paperna T, Gershoni-Baruch R, Badarneh K, et al. Mutations in CYP11B1 and congenital adrenal hyperplasia in Moroccan Jews. J Clin Endocrinol Metab 2005; 90:5463-5465. (Pubitemid 41262316)
94. Kagimoto M, Winter JS, Kagimoto K, et al. Structural characterization of normal and mutant human steroid 17 alpha-hydroxylase genes: Molecular basis of one example of combined 17 alpha-hydroxylase/17,20 lyase deficiency. Mol Endocrinol 1988; 2:564-570.
95. Imai T, Yanase T, Waterman MR, et al. Canadian Mennonites and individuals residing in the Friesland region of The Netherlands share the same molecular basis of 17 alpha-hydroxylase deficiency. Hum Genet 1992; 89:95-96.
96. Dhir V, Reisch N, Bleicken CM, et al. Steroid 17alpha-hydroxylase deficiency: Functional characterization of four mutations (A174E, V178D, R440C, L465P) in the CYP17A1 gene. J Clin Endocrinol Metab 2009; 94:3058-3064. This paper outlines the presentations of three cases of 11β-hydroxylase deficiency and two novel mutations.
97. Mein CA, Caulfield MJ, Dobson RJ, Munroe PB. Genetics of essential hypertension. Hum Mol Genet 2004; 13:R169-R175. (Pubitemid 38443811)
98. Kurtz TW. Genome-wide association studies will unlock the genetic basis of hypertension: Con side of the argument. Hypertension 2010; 56:1021-1025. This review eloquently sets out the case against the strategy of using genome-wide association studies to identify common alleles causing essential hypertension, in favour of using approaches targeted on candidate alleles identified from rare monogenic disorders.
99. Quinkler M, Stewart PM. Hypertension and the cortisol-cortisone shuttle. J Clin Endocrinol Metab 2003; 88:2384-2392. (Pubitemid 36724401)
100. Ferrari P. The role of 11beta-hydroxysteroid dehydrogenase type 2 in human hypertension. Biochim Biophys Acta 2010; 1802:1178-1187. Recent review on 11b-HSD2 in all aspects of hypertension.
101. Mariniello B, Ronconi V, Sardu C, et al. Analysis of the 11beta-hydroxysteroid dehydrogenase type 2 gene (HSD11B2) in human essential hypertension. Am J Hypertens 2005; 18:1091-1098. (Pubitemid 41139908)
102. McTernan CL, Draper N, Nicholson H, et al. Reduced placental 11betahydroxysteroid dehydrogenase type 2 mRNA levels in human pregnancies complicated by intrauterine growth restriction: An analysis of possible mechanisms. J Clin Endocrinol Metab 2001; 86:4979-4983. (Pubitemid 33020553)
103. Barker WH, Mullooly JP, Linton KL. Trends in hypertension prevalence, treatment, and control: In a well defined older population. Hypertension 1998; 31 (1 Pt 2):552-559.
104. Martinez F, Mansego ML, Escudero JC, et al. Association of a mineralocorticoid receptor gene polymorphism with hypertension in a Spanish population. Am J Hypertens 2009; 22:649-655. Mineralocorticoid receptor gene SNPs are shown to be predictive of blood pressure in this study of 1502 Spanish study participants.
105. Lin RC, Wang WY, Morris BJ. Association and linkage analyses of glucocorticoid receptor gene markers in essential hypertension. Hypertension 1999; 34:1186-1192. (Pubitemid 30002380)